Clinical Research Directory
Browse clinical research sites, groups, and studies.
NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome
Sponsor: Stephen G. Kaler, MD
Summary
The purpose of this study is to evaluate whether Northera (Droxidopa) is safe and effective in young adults with Menkes disease who survived the most severe complications of their illness or adults with occipital horn syndrome (OHS), who have trouble with intermittent low blood pressure and other symptoms of dysautonomia. The outcomes and information from this study may help adult survivors of Menkes disease and individuals with OHS lead more normal day-to-day lives.
Official title: Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Adults With Occipital Horn Syndrome: Double-blind Placebo-controlled Randomized Crossover Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
3
Start Date
2021-07-12
Completion Date
2024-06-29
Last Updated
2026-04-13
Healthy Volunteers
No
Conditions
Interventions
Droxidopa
Subjects will self-administer capsules of Droxidopa by mouth twice daily for six weeks.
Placebo
Subjects will self-administer capsules of placebo by mouth twice daily for six weeks.
Locations (1)
Vagelos College of Physicians and Surgeons, Columbia University
New York, New York, United States